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Background and aims: Metabolic Syndrome (MS) is increasing in developing countries. Different defi-
nitions of MS lead to discrepancies in prevalence estimates and applicability. We assessed the prevalence
of MS as defined by the International Diabetes Federation (IDF), modified National Cholesterol Education
Program Adult Treatment Plan III (Modified NCEP) and Joint Interim Statement (JIS); compared the
diagnostic performance and association of these definitions of MS with pre-diabetes, type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD) risk.
Methods: A total of 714 randomly selected subjects from Northeastern Brazil were investigated in a
cross-sectional study. Sociodemographic, anthropometric, and clinical data were recorded. Diagnostic
test performance measures assessed the ability of the different MS definitions to identify those with pre-
diabetes, T2DM and increased CVD risk.
Results: The adjusted prevalence of MS was 36.1% applying the JIS criteria, 35.1% the IDF and 29.5%
Modified NCEP. Women were more affected by MS according to all definitions. MS was significantly
associated with pre-diabetes, T2DM and CVD risk following the three definitions. However, the JIS and
IDF definitions showed higher sensitivity than the Modified NCEP to identify pre-diabetes, T2DM and
CVD risk. The odds ratios for those conditions were not significantly different when comparing the
definitions.
Conclusions: MS is highly prevalent in Brazil, particularly among those with pre-diabetes, T2DM, and
high CVD risk. The IDF and JIS criteria may be better suited in the Brazilian population to identify pre-
diabetes, T2DM and CVD risk. This may also signify the importance of the assessment of MS in clinical
practice.
© 2020 The Authors. Published by Elsevier Ltd on behalf of Diabetes India. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Metabolic syndrome (MS) is characterized by a clustering of
interrelated risk factors including abdominal obesity, hyperglyce-
mia, hypertension, and dyslipidemia [1]. The condition is associated6, 60.175.415, Fortaleza, CE,
. do Vale Moreira).
r Ltd on behalf of Diabetes India. Twith an increased risk of type 2 diabetes mellitus (T2DM), cardio-
vascular events and deaths [2].
The prevalence of MS has grown worldwide, and it is estimated
that approximately 20e25% of theworld’s population hasMS [3]. In
developing countries, especially in South America, rapid socioeco-
nomic and demographic transitions have fostered great increases in
obesity rates, sedentary lifestyles, as well as profound changes in
dietary patterns [4]. Studies conducted in Latin American countries
as Chile, Colombia, Mexico, Peru and Venezuela showed a highhis is an open access article under the CC BY license (http://creativecommons.org/
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according to a systematic review from 2013, the weighted mean
prevalence of MS was 29.6% (range: 14.9%e65.3%) [10].
Different definitions of MS have been proposed so far and,
therefore, prevalence estimates may vary substantially across
populations, depending not only on their characteristics, but
specially on the diagnostic criteria applied. The most commonly
used definitions have been produced by the National Cholesterol
Education Program Adult Treatment Panel III (NCEP) in 2001 [11],
which was updated in 2005 by the American Heart Association/
National Heart, Lung, and Blood Institute (Modified NCEP) [12], and
the International Diabetes Federation (IDF) [13]. Even though the
definitions share common features, several parameters differ,
which leads to discrepancies in applicability, uniformity, and pos-
itive predictive value [14]. More recently, a Joint Interim Statement
(JIS) issued by several scientific societies has attempted to develop a
unifying definition of MS [2].
Although the MS has been considered a major global health
problem, many uncertainties and controversies remain. MS has
been pointed out as an ill-characterized entity, with no clear
rationale for thresholds [15]. Furthermore, its value as a risk
assessment tool for future cardiovascular disease (CVD) has been
claimed as weak [16], or no greater than the sum of its components
[17]. Although the syndrome is effective in predicting diabetes, its
predictive value beyond that of glucose intolerance has also been
questioned [15]. In Brazil, few studies have described the preva-
lence of MS and its determinants. More importantly, there is scarce
information about the applicability and agreement of different
definitions of MS, as well as their predictive value in the estimation
of T2DM, pre-diabetes, and CVD risk in the Brazilian population.
Therefore, we aimed to determine the prevalence of MS as defined
by the Modified NCEP [12], the IDF [13], and JIS [2]; assess the
agreement between the definitions; and investigate the association
of MS with pre-diabetes, T2DM and CVD risk. It was hypothesized
that the JIS will show a higher prevalence of MS, as well as greater
sensitivity to predict the cases of diabetes, pre-diabetes, and high
CVD risk.
2. Subjects
This population-based study was conducted in the city of Pin-
doretama, in the northeast region of Brazil, between August 2012
and January 2013. The recruitment methods and examination
procedures have been described beforehand [18]. The data were
collected in the six main health centers located throughout the city.
Subjects of both genders, aged 20 years, able to verbally
communicate and willing to participate were eligible to enter the
study. Exclusion criteria were those with acute or chronic severe
cardiac, renal, or hepatic illness, pregnant women, and physically or
mentally disabled individuals.
A registry list with the names of Pindoretama’s citizens in
alphabetic orderwas provided by the health authorities and used to
select the potential participants. Random numbers were produced
with the software R [19] and identified with the names in the list
subsequently. Eight hundred and six subjects were randomly
selected and of these, 714 agreed to participate (response rate of
88.6%). Owing to the different criteria applied by each MS defini-
tion, the total number of recorded observations was n ¼ 707
following the IDF, and n¼ 704 according to both theModified NCEP
and JIS definitions. On recruitment, participants were requested by
the community health workers to visit a nearby health center, after
an overnight fast of 8e10 h. Sociodemographic, clinical, and
nutritional data were collected by trained interviewers using pre-
tested questionnaires. Anthropometric, blood pressure (BP) and
body fat percentage (BF%) measurements were also taken.3. Materials and methods
3.1. Measurements
Anthropometric measurements including height, weight, waist
circumference (WC) and hip circumference (HC) were taken with
subjects standing in bare feet and with light clothes. Weight was
taken by using a portable digital scale, calibrated before use, placed
on a flat surface, and recorded to the nearest 0.1 Kg. A well-
mounted stadiometer was applied to measure height, with the
participant looking straight and in erect position. Height was
recorded to the nearest 0.1 cm. The body mass index (BMI) was
estimated as the weight in kilograms divided by the square of
height in meters (Kg/m2). The BF% was assessed by a portable bi-
polar body fat analyzer (Omron®, Model HBF-306, Omron
Healthcare, Inc., Illinois, United States). TheWCwas measured with
a non-stretchable tape, positioned horizontally midway between
the lower border of the ribs and iliac crest, on the mid-axillary line.
The HC was assessed by placing the same tape at the greatest
protrusion of the buttocks, with the subject standing straight. WC
and HCwere registered to the nearest 0.1 cm. Thewaist-to-hip ratio
(WHR) was calculated as the WC divided by the HC. The BP was
estimated twice, by using an electronic sphygmomanometer
(Omron® BP785 IntelliSense® Automatic Blood Pressure Monitor
with ComFitTM Cuff, Omron Healthcare, Inc., Illinois, United States).
The first measurement was taken after a resting time of at least
15min, and the second about 10min after the first. The mean of the
two values was used for analysis.
On arrival at the field center, a 10-mL fasting venous blood sample
was collected for measuring fasting plasma glucose (FPG) levels and
other relevant laboratory tests. Two hours after a 75 g oral glucose
load, another venous samplewasdrawn for the oral glucose tolerance
test (OGTT). Fasting and 2-h plasma glucose levels were assessed by
the glucose oxidasemethod, whereas fasting insulinwas determined
by chemiluminescence. Total cholesterol (TC) was estimated by the
cholesterol oxidase - phenol þ aminophenazone (CHOD-PAP)
method, while high-density lipoprotein cholesterol (HDL-C) was
determined by a homogenous enzymatic colorimetric method. Tri-
glycerides (TG) were determined by the glycerol-3-phosphate oxi-
dase - phenol þ aminophenazone (GPO-PAP) method. Low-density
lipoprotein cholesterol (LDL-C) was calculated by the Friedewald
Formula [20]. Laboratory quality control was assessed internally and
externally.
3.2. Definition of variables and outcomes
MSwas defined following the diagnostic criteria as suggested by
the Modified NCEP [12], IDF [13], and JIS [2]. The three definitions
are described in Table 1. Contrary to the Modified NCEP and JIS
definitions, IDF considers abdominal obesity a prerequisite for
diagnosing MS. Furthermore, the IDF definition applies ethnic-
specific WC cut-off points as the measure of central obesity. For
South and Central Americans, until population-specific data are
available, IDF recommends using South Asian cut-off points, i.e.,
WC  90 cm in men and 80 cm in women. Therefore, for the
Modified NCEP definition, the WC cut-off points applied in this
study were 102 cm in men and 88 cm in women, whereas for
the IDF definitionwereWC 90 cm in men and80 cm inwomen.
The JIS definition recommends that the IDF cut points for central
obesity should be used for non-Europeans in case there is no
country-specific data available. Since no WC cut-off points of risk
for MS have been established for the Brazilian population, the IDF
recommended cut points were also used here for the JIS definition.
Physical activity data were assessed by the International Phys-
ical Activity Questionnaire (IPAQ) short form [21]. Following the
Table 1
Criteria for clinical diagnosis of the MS following different definitions.
Risk
Factors




Abdominal obesity plus 2 or more risk factors Any 3 or more of 5 risk factors Any 3 or more of 5 risk factors
1 Central
Obesity
WC  90 cm in males,  80 cm in females WC  102 cm in males,  88 cm in females WC  90 cm in males,  80 cm in females
2 TG 1.7 mmol/l (150 mg/dl) or on specific treatment
for elevated TG
1.7 mmol/l (150 mg/dl) or on drug treatment for
elevated TG
1.7 mmol/l (150 mg/dl) or on drug treatment for
elevated TG
3 HDL-C <1.03 mmol/l (40 mg/dl) in males, < 1.30 mmol/l
(50 mg/dl) in females or on drug treatment for
reduced HDL-C
<1.03 mmol/l (40 mg/dl) in males, < 1.30 mmol/l
(50 mg/dl) in females or on drug treatment for
reduced HDL-C
<1.03 mmol/l (40 mg/dl) in males, < 1.30 mmol/l




SBP  130 mmHg or DBP  85 mmHg or
treatment of previously diagnosed hypertension
SBP 130mmHg or DBP 85mmHg or current use of
antihypertensive drugs in a patient with a history of
hypertension
SBP  130 mmHg or DBP  85 mmHg or
antihypertensive drug treatment in a patient with a
history of hypertension
5 FG Fasting plasma glucose  5.6 mmol/l (100 mg/dl)
or previously diagnosed Type 2 diabetes
5.6 mmol/L (100 mg/dL) or on drug treatment for
elevated glucose
5.6 mmol/L (100 mg/dL) or on drug treatment for
elevated glucose
DBP: Diastolic Blood Pressure. FG: Fasting Glucose. HDL-C: High-Density Lipoprotein Cholesterol. IDF: International Diabetes Federation. JIS: Joint Interim Statement. MS:
Metabolic Syndrome. NCEP: National Cholesterol Education Program Expert Panel. SBP: Systolic Blood Pressure. TG: Triglycerides. WC: Waist Circumference.
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ethnicity was defined according to the participants’ self-perception
of their skin color. The different ethnic groups were categorized
into “white”, “brown”, and “black” [22].
The 1999 WHO criteria were applied in diagnosing diabetes
mellitus, impaired fasting glycaemia (IFG) and/or impaired glucose
tolerance (IGT). Diabetes cases were those who were previously
diagnosed, or those with fasting (venous) plasma glucose
value  7.0 mmol/l (126 mg/dl), or the plasma glucose value 2 h
after a 75 g oral glucose load  11.1 mmol/l (200 mg/dl), or both.
IGT was determined when FPG <7.0 mmol/l (<126 mg/dl), and 2-h
plasma glucose 7.8 mmol/l (140 mg/dl), but <11.1 mmol/l
(<200 mg/dl). IFG was defined as FPG 6.1 mmol/l (110 mg/dl),
but <7.0 mmol/l (<126 mg/dl), and 2-h plasma glucose <7.8 mmol/l
(<140 mg/dl). Individuals with IFG and/or IGT were classified as
pre-diabetes cases [23].
Dyslipidemia was described as TG  1.7 mmol/l and HDL-C <
0.9 mmol/l for men; and <1.0 mmol/l for women [23]. Insulin
resistance was calculated with the homeostasis model assessment
of insulin resistance (HOMA-IR ¼ [insulin (mU/l)  glucose (mmol/
l)]/22.5) [24]. The 10-year risk of CVD was calculated for each
participant using a 2008 Framingham risk equation. The model
predictors for the gender-specific algorithm included age, TC, HDL-
C, systolic BP, antihypertensive medication use, smoking and dia-
betes status [25]. Individuals with a Framingham predicted risk for
an incident cardiovascular event of 10% or above during the next 10
years were described as having high CVD risk. Thirteen subjects
reported a history of stroke and/or myocardial infarction and were
excluded from the analysis for CVD risk.
3.3. Ethics
The study was carried out according to the guidelines laid down
in the Declaration of Helsinki [26], and the protocol was approved
by both the local Ethical Committee in Brazil (Protocol Number:
045.06.12) and the Regional Committee for Medical and Health
Research Ethics (REK) in Norway (Reference: 2012/779/REK sør-øst
D). Written or verbal consent was obtained from each subject
before any investigation. The participants were also informed of
their right to withdraw from the study at any stage, or to omit their
data from the analysis. All the names in the registration list were
removed before the analyses were performed. Those diagnosed
with any clinical condition were referred to the nearest health
center for proper treatment and further follow up.3.4. Statistical Analysis
Means and 95% confidence interval (CI) were given for numer-
ical data, while percentages and 95% CI for categorical variables.
Generalized linear regression models (GLM) were fitted to the data
after adjusting for age and gender. In particular, we fitted GLMs
with linear link function for comparing differences between
adjusted means and GLMs with the logit link function to compare
differences between proportions. Following estimation of the
adjusted logistic regression models, the prevalence of MS was ob-
tained as margins. Kappa statistics measured the agreement be-
tween the three MS definitions [27]. Diagnostic test performance
measures including sensitivity, specificity, accuracy, positive pre-
dictive value (PPV) and negative predictive value (NPV) were
calculated using contingency tables. Adjusted odds ratios (ORs)
were calculated based on the IDF, Modified NCEP and JIS definitions
for pre-diabetes, T2DM, and CVD risk. Adjusted ORs were obtained
by applying logistic regression analysis controlling for age, gender,
and BMI. The significance level was set at 0.05. All tests were two-
sided. Statistical analyses were performed by using SPSS 25th
version [28] and Stata 15th edition [29].
4. Results
As can be seen in Table 2, substantial differences were found in
demographic, lifestyle, anthropometric and cardiometabolic char-
acteristics between those with and without MS. Comparing only
those with MS, the mean WC (p-value: 0.035) and BMI (p-value:
0.039) were significantly higher using the Modified NCEP criteria
than when the JIS definition was applied.
Irrespective of which definition was applied, the prevalence of
MS among women (ranging from 38.2 to 44.8%) was significantly
higher than in men (ranging from 12.6 to 18.9%) (Table 3). Ac-
cording to all three definitions, the prevalence increased signifi-
cantly with age, BMI status, and level of income. However, the
prevalence did not differ significantly among ethnic groups. Using
the Modified NCEP definition, those with 10 years of education
showed a significantly lower odds for MS than thosewith <10 years
(OR ¼ 0.6, 95% CI: 0.4e0.9; p-value: 0.019).
Table 4 shows the overall prevalence of MS, as well as the
prevalence of MS among those with pre-diabetes, T2DM and high
CVD risk. The age- and gender-adjusted prevalence was highest
applying the definition described by the JIS (36.1%), followed by the
IDF (35.1%) and Modified NCEP (29.5%). Nevertheless, these
Table 2
Cardiometabolic, anthropometric and lifestyle characteristics of the study participants with and without MS, applying the criteria as described by the IDF, Modified NCEP and
JIS.
Variables IDFa Modified NCEPa JISa
With MS Without MS With MS Without MS With MS Without MS
n 248 459 208 496 254 450
Age (years) 52.4 (50.5e54.3)** 41.1 (39.7e42.5) 53.0 (50.8e55.1)** 41.8 (40.5e43.2) 52.7 (50.8e54.6)** 40.9 (39.4e42.3)
Gender (female), % (95% CI) 84.1 (79.6e88.5)** 55.6 (51.0e60.1) 87.1 (82.7e91.5)** 56.7 (52.3e61.1) 84.2 (79.9e88.6)** 55.1 (50.5e59.8)
Smoking (yes)b 36.5 (30.9e42.1) 41.7 (37.4e46.0) 37.7 (31.6e43.9) 40.9 (36.8e45.0) 36.5 (30.9e42.0) 42.1 (37.7e46.4)
Alcohol Consumption (yes) 39.2 (32.9e45.4) 34.9 (30.9e38.9) 39.8 (32.9e46.6) 35.0 (31.2e38.8) 39.0 (32.8e45.1) 35.0 (31.0e39.0)
Physical Activity
Low 77.2 (71.5e82.8)** 61.1 (56.6e65.7) 82.2 (76.6e87.9)** 60.2 (55.8e64.6) 77.3 (71.7e82.9)** 60.6 (56.0e65.2)
Moderate/High 22.8 (17.2e28.5) 38.9 (34.3e43.4) 17.8 (12.1e23.4) 39.8 (35.4e44.2) 22.7 (17.1e28.3) 39.4 (34.8e44.0)
BMI (kg/m2) 29.6 (28.9e30.2)** 25.4 (25.0e25.9) 30.4 (29.7e31.0)** 25.4 (25.0e25.9) 29.4 (28.8e30.0)** 25.5 (25.0e25.9)
WC (cm) 97.2 (95.7e98.8)** 86.1 (85.0e87.2) 98.9 (97.3e100.6)** 86.4 (85.3e87.4) 96.7 (95.1e98.2)** 86.4 (85.2e87.5)
WHR, mean (95% CI) 0.95 (0.94e0.96)** 0.90 (0.89e0.91) 0.96 (0.95e0.97)** 0.90 (0.89e0.91) 0.95 (0.93e0.96)** 0.90 (0.89e0.91)
BF%, mean (95% CI) 35.1 (34.2e36.0)** 31.5 (30.9e32.2) 35.6 (34.6e36.6)** 31.7 (31.1e32.3) 34.9 (34.0e35.8)** 31.7 (31.0e32.3)












DBP (mmHg) 83.9 (81.7e86.1)** 72.9 (71.3e74.4) 83.3 (80.8e85.7)** 74.0 (72.5e75.6) 84.0 (81.9e86.2)** 72.7 (71.1e74.3)
FPG (mmol/l) 6.5 (6.2e6.8)** 4.9 (4.7e5.1) 6.9 (6.5e7.2)** 4.9 (4.7e5.1) 6.6 (6.3e6.9)** 4.8 (4.6e5.1)
2-hour Post Glucose Load (mmol/l) 9.6 (9.1e10.2)** 6.9 (6.5e7.3) 10.3 (9.7e10.9)** 6.8 (6.5e7.2) 9.8 (9.2e10.3)** 6.8 (6.4e7.2)
Fasting Insulin (micro UI/ml) 8.6 (8.0e9.3)** 5.7 (5.2e6.2) 8.9 (8.2e9.6)** 5.8 (5.4e6.3) 8.5 (7.9e9.2)** 5.7 (5.3e6.2)
HOMA-IR 2.4 (2.3e2.6)** 1.2 (1.1e1.3) 2.6 (2.4e2.8)** 1.2 (1.1e1.4) 2.4 (2.2e2.6)** 1.2 (1.1e1.3)
Total Cholesterol (mmol/l) 5.0 (4.9e5.1)** 4.5 (4.4e4.6) 5.1 (4.9e5.2)** 4.6 (4.5e4.6) 5.0 (4.9e5.2)** 4.5 (4.4e4.6)
HDL-C (mmol/l) 1.19 (1.17e1.20)** 1.24 (1.23e1.26) 1.19 (1.17e1.20)** 1.24 (1.23e1.25) 1.18 (1.17e1.20)** 1.25 (1.23e1.26)
LDL-C (mmol/l) 2.9 (2.8e3.0) 2.8 (2.7e2.9) 3.0 (2.8e3.1) 2.8 (2.7e2.9) 2.9 (2.8e3.1) 2.8 (2.7e2.9)
Triglycerides (mmol/l) 2.4 (2.2e2.6)** 1.1 (0.9e1.2) 2.5 (2.3e2.7)** 1.1 (1.0e1.2) 2.4 (2.2e2.6)** 1.0 (0.9e1.1)
Dyslipidemia, % (95% CI) 56.8 (50.3e63.3)** 9.6 (7.0e12.2) 60.5 (53.5e67.5)** 11.3 (8.6e14.1) 58.6 (52.2e64.9)** 8.3 (5.9e10.7)
Data are mean (95% confidence interval) or percentage (95% confidence interval), adjusted for age and gender; a The number of observations recorded was 707 for the IDF
definition, 704 for both Modified NCEP ATP III and JIS; b Included those who self-reported as being smokers or had stopped smoking for less than 1 year; The values were
significantly different between those with and without MS at **p < 0.01 or *p < 0.05, by logistic regression analysis; BF%: Body Fat Percentage. BMI: Body Mass Index. CI:
Confidence Interval. DBP: Diastolic Blood Pressure. FPG: Fasting Plasma Glucose. HDL-C: High-Density Lipoprotein Cholesterol. HOMA-IR: Homeostasis Model Assessment of
Insulin Resistance. IDF: International Diabetes Federation. JIS: Joint Interim Statement. LDL-C: Low-Density Lipoprotein Cholesterol. MS: Metabolic Syndrome. NCEP: National
Cholesterol Education Program Expert Panel. SBP: Systolic Blood Pressure. WC: Waist Circumference. WHR: Waist-to-Hip Ratio.
Table 3
Prevalence of MS by demographic and socioeconomic characteristics, age- and gender-adjusted.
n IDF Modified NCEP JIS
Gender
Male 242 18.3 (13.6e23.0)** 12.6 (8.5e16.7)** 18.9 (14.2e23.7)**
Female 472 43.7 (39.5e47.9) 38.2 (34.1e42.3) 44.8 (40.7e49.0)
Age Groups
20e35 235 18.5 (13.6e23.3)** 13.8 (9.4e18.1)** 18.5 (13.6e23.4)**
36e50 241 32.6 (26.9e38.4) 28.7 (23.2e34.2) 33.3 (27.6e39.1)
51 238 54.0 (48.1e60.0) 46.0 (40.0e51.9) 56.2 (50.2e62.1)
BMI Status
<25 kg/m2 272 16.7 (12.5e20.8)** 9.7 (6.4e13.1)** 18.7 (14.4e23.0)**
25e29.99 kg/m2 266 38.5 (33.2e43.9) 30.9 (25.9e35.9) 38.9 (33.7e44.2)
30 kg/m2 175 58.3 (51.6e64.9) 57.7 (51.2e64.3) 58.3 (51.7e64.9)
Ethnicity
White 120 37.8 (29.9e45.8) 32.8 (25.1e40.5) 39.5 (31.6e47.4)
Brown 576 34.7 (31.2e38.3) 29.1 (25.7e32.5) 35.6 (32.1e39.2)
Black 18 27.8 (9.0e46.6) 22.2 (4.7e39.8) 27.8 (9.1e46.5)
Education
<10 years 508 40.4 (36.5e44.4) 34.8 (31.0e38.6)* 41.8 (37.9e45.7)
10 years 206 22.0 (16.5e27.4) 16.7 (11.7e21.6) 22.1 (16.6e27.5)
Monthly Income
<2 MW 641 34.2 (30.8e37.5)** 28.8 (25.6e31.9)** 35.2 (31.9e38.6)**
2 MW 71 44.3 (33.9e54.6) 37.7 (27.6e47.7) 44.9 (34.5e55.3)
Data are provided as % (95% confidence interval) adjusted for age and gender; **p < 0.001 and *p < 0.05, by logistic regression analysis; BMI: Body Mass Index. IDF: Inter-
national Diabetes Federation. JIS: Joint Interim Statement. MS: Metabolic Syndrome. MW: MinimumWage in 2012, that corresponds currently to US$ 162.00. NCEP: National
Cholesterol Education Program Expert Panel.
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recommended by the JIS, MS was present in 58.2% of subjects
diagnosed with pre-diabetes, 76.1% of those with T2DM, and 57.1%
of those with high CVD risk. Following the IDF definition, the
respective parameters were 57.1, 74.3, 54.8%, while for the Modified
NCEP, the values were 46.9, 70.8, and 48.0%. The agreement washighest between the definitions described by the IDF and JIS, as
measured by the kappa statistics (overall study population and pre-
diabetes: 0.98; T2DM and high CVD risk: 0.95). The lowest agree-
ment was observed between the IDF and Modified NCEP defini-
tions, both for overall (0.83) and all other subsets of the study
population (pre-diabetes: 0.76; T2DM: 0.82; high CVD risk: 0.77).
Table 4
Adjusted prevalence of MS among overall, subjects with pre-diabetes, T2DM and high CVD risk, as well as the agreement between the definitions of MS as described by the IDF,
Modified NCEP and JIS.
IDF Modified NCEP JIS IDF vs.
Modified NCEP
Modified NCEP vs. JIS IDF vs. JIS
n % (95% CI) % (95% CI) % (95% CI) Kappa (p-value) Kappa (p-value) Kappa (p-value)
Overall 714 35.1 (31.9e38.3) 29.5 (26.5e32.6) 36.1 (32.9e39.3) 0.83 (<0.001) 0.85 (<0.001) 0.98 (<0.001)
Pre-Diabetes 100 57.1 (48.0e66.3) 46.9 (37.8e56.1) 58.2 (49.1e67.2) 0.76 (<0.001) 0.78 (<0.001) 0.98 (<0.001)
T2DM 114 74.3 (66.9e81.8) 70.8 (63.2e78.4) 76.1 (68.9e83.3) 0.82 (<0.001) 0.86 (<0.001) 0.95 (<0.001)
High CVD Riska 254 54.8 (49.3e60.2) 48.0 (42.6e53.4) 57.1 (51.8e62.5) 0.77 (<0.001) 0.82 (<0.001) 0.95 (<0.001)
Data presented as percentage (95% confidence interval) adjusted for age and gender.
a The 10-year risk of CVD was calculated using a 2008 Framingham risk equation. Those with a history of stroke and/or myocardial infarction were excluded from the
analysis; CI: Confidence Interval. CVD: Cardiovascular Disease. IDF: International Diabetes Federation. JIS: Joint Interim Statement. MS: Metabolic Syndrome. NCEP: National
Cholesterol Education Program Expert Panel. T2DM: Type 2 Diabetes Mellitus.
Table 6
Odds rations (OR) for pre-diabetes, T2DM, and people with high CVD risk in those
with MS compared with those without MS.
Pre-Diabetes T2DM High CVD Risk
OR (95% CI) OR (95% CI) OR (95% CI)
IDF 3.9 (2.3e6.5)a 5.0 (3.0e8.5)a 5.6 (2.9e10.9)a
Modified NCEP 3.6 (2.0e6.2)a 6.4 (3.7e11.1)a 5.7 (2.9e11.3)a
JIS 3.9 (2.3e6.5)a 5.4 (3.2e9.3)a 7.1 (3.6e14.2)a
Adjusted for age, gender, and body mass index.
a p < 0.001; CI: Confidence Interval. CVD: Cardiovascular Disease. IDF: Interna-
tional Diabetes Federation. JIS: Joint Interim Statement. MS: Metabolic Syndrome.
NCEP: National Cholesterol Education Program Expert Panel. T2DM: Type 2 Diabetes
Mellitus.
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diagnose pre-diabetes, T2DM and high CVD risk are presented in
Table 5. The JIS definition showed a greater sensitivity than the
Modified NCEP to identify pre-diabetes (58.2% vs 46.9%), T2DM
(76.1% vs 70.8%) and high CVD risk (57.1% vs 48%). However,
following the Modified NCEP definition, the specificity (pre-dia-
betes: 83.4%; T2DM: 78.3%; high CVD risk: 81.2%) and PPV (pre-
diabetes: 31.5%; T2DM: 38.4%; high CVD risk: 59.1%) were higher
thanwhen the JIS definitionwas applied. The IDF and JIS definitions
showed similar results regarding sensitivity, specificity, PPV and
NPV.
Table 6 presents the ORs of the IDF, Modified NCEP and JIS
definitions for pre-diabetes, T2DM, and high CVD risk using logistic
regression analysis after adjustment for age, gender, and BMI. A
significant association was found between MS and pre-diabetes,
T2DM and high CVD risk, irrespective of which definition of MS
was applied. The adjusted ORs for pre-diabetes (ranging from 3.6 to
3.9), T2DM (5.0e6.4) and high CVD risk (5.6e7.1) were not signif-
icantly different between the different definitions of MS.5. Discussion
To the best of our knowledge, this is one of the first population-
based study from Brazil to compare the prevalence of MS among
subjects with pre-diabetes, T2DM and high CVD risk, following the
recent JIS criteria in relation to other more established definitions.
We found a high prevalence of MS in the overall population, andTable 5
Diagnostic performance of the IDF, Modified NCEP and JIS definitions of MS to predict pr
Pre-Diabetes
IDF
Sensitivity, % (95% CI) 57.1 (46.8e67.1)
Specificity, % (95% CI) 78.2 (74.3e81.8)
Positive Predictive Value, % (95% CI) 29.9 (22.9e37.7)
Negative Predictive Value, % (95% CI) 91.8 (88.8e94.2)
Accuracy (%) 75.2
Modified NCEP
Sensitivity, % (95% CI) 46.9 (36.8e57.3)
Specificity, % (95% CI) 83.4 (79.8e86.6)
Positive Predictive Value, % (95% CI) 31.5 (23.4e40.5)
Negative Predictive Value, % (95% CI) 90.6 (87.6e93.1)
Accuracy (%) 78.3
JIS
Sensitivity, % (95% CI) 58.2 (47.8e68.1)
Specificity, % (95% CI) 77.5 (73.5e81.1)
Positive Predictive Value, % (95% CI) 29.6 (22.7e37.3)
Negative Predictive Value, % (95% CI) 91.9 (88.9e94.3)
Accuracy (%) 74.8
CI: Confidence Interval. CVD: Cardiovascular Disease. IDF: International Diabetes Federatio
Education Program Expert Panel. T2DM: Type 2 Diabetes Mellitus.particularly among the participants with pre-diabetes, T2DM, and
high CVD risk. Women and those with a higher income were
disproportionately affected. The agreement between all three def-
initions was almost perfect. The JIS and IDF definitions showed a
higher sensitivity to identify the subjects with pre-diabetes, T2DM
and high CVD risk.
In the current study, the observed prevalence of MS was higher
than the estimated prevalence of 20e25% for the global population
[3]. Following the Modified NCEP definition, the overall prevalence
of MS in our study population (29.5%) was somewhat lower than
that in the US population (34.7%), reported by the 2003e2012
National Health and Nutrition Examination Survey (NHANES) [30].
Compared to other middle-income countries, using the IDFe-diabetes, T2DM, and people with high CVD risk in an adult Brazilian population.
T2DM High CVD Risk
74.3 (65.3e82.1) 54.8 (48.4e61.0)
72.4 (68.6e76.0) 76.6 (72.3e80.5)
33.9 (28.0e40.2) 57.1 (50.5e63.4)
93.7 (91.0e95.7) 74.9 (70.6e78.9)
72.7 68.7
70.8 (61.5e79.0) 48.0 (41.7e54.4)
78.3 (74.8e81.6) 81.2 (77.2e84.7)
38.4 (31.7e45.4) 59.1 (52.0e66.0)
93.4 (90.8e95.4) 73.3 (69.2e77.2)
77.1 69.2
76.1 (67.2e83.6) 57.1 (50.8e63.3)
71.6 (67.8e75.2) 76.6 (72.3e80.5)
33.8 (28.0e40.0) 58.0 (51.6e64.3)
94.0 (91.4e96.0) 75.9 (71.6e79.8)
72.3 69.5
n. JIS: Joint Interim Statement. MS:Metabolic Syndrome. NCEP: National Cholesterol
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was similar to that reported from Colombia 32.9% [6], lower than
Mexico (49.8%) [31], higher than India (25.8%) [32] and China (9.8%
in men; 16.6% inwomen) [33]. According to the JIS definition, 36.1%
of the subjects were classified as having MS, which was slightly
higher than that observed in central Brazil (32%) [34]. In addition to
methodological differences, the varied prevalence rates of MS
across populations may be explained by different demographic,
epidemiological and nutritional transitions [35], as well as envi-
ronmental, social [36] and ethnic disparities [37].
Although the prevalence of MS did not differ significantly be-
tween the three definitions, it was highest when using the criteria
described by the JIS and lowest following the Modified NCEP. The
observed higher prevalence of MS obtained using the JIS criteria
compared to the Modified NCEP may be due to the higher rate of
central obesity identified by the lower WC cut points used for the
JIS [2]. Furthermore, the MS prevalence was also somewhat higher
according to the IDF definition than the Modified NCEP definition.
The IDF criteria places more emphasis on central obesity in the
definition of the MS and recommends lower WC cut-off points for
South America similarly to the JIS definition [13].
Following all three definitions, the prevalence of MS was
significantly higher among women than men, which has also been
found elsewhere [31,33,38]. This was especially evident for the
prevalence following the IDF (43.7% vs 18.3%; p-value < 0.001) and
JIS (44.8% vs 18.9%; p-value < 0.001) definitions. Central obesity has
been strongly correlated with insulin resistance and MS [13]. In our
study population, as shown in Supplementary Table 1, women had
a significantly higher prevalence of abdominal obesity when
applying both the different recommended WC cut-off points of
90 cm for males;  80 cm for females (81.7% vs 52.1%) and of
102 cm for males;  88 cm for females (56.9% vs 14.9%).
Furthermore, women also showed significantly higher rates of ab-
normalities in glucose metabolism (27.8% vs 18.7%) and HDL-C
levels (73.5% vs 4.1%) (Supplementary Table 1). Nevertheless, this
gender difference was not observed in another study conducted
among 2130 adults in central Brazil [34]. The study involved a
younger population, with less than 12,5% of women aged 50
years, compared to approximately 33% in our data. Furthermore,
metabolic changes related to menopause have been linked to an
increased risk of MS and CVD [39] andmight also explain the higher
prevalence of MS among females in our findings.
In this study, the prevalence of MS increased significantly and
progressively with age and BMI status, which has been found by
several [31,34,40,41]. In contrast with some studies from South-
eastern Brazil [42,43], we identified an increasing rate of MS with
higher levels of income, following all the definitions. Nevertheless,
a study from India among 1178 adults, aged 20e80 years, also found
that middle-to-high income significantly contributed to increased
risk of MS [44]. In our sample, ethnicity was not an important
predictor of MS. One possible reason may be the high degree of
heterogeneity and mixed genetic composition of the Brazilian
population. Due to five centuries of miscegenation, the country’s
population consists of interethnic admixtures of people from Eu-
ropean, African and native American origins [45]. Although the
relative genetic contribution of these diverse ethnic backgrounds
may vary across the different regions in Brazil, a study from the
Southeast among 1507 individuals found similar results [42].
Consistent with other studies [38,46,47] and as expected, we
observed a higher frequency of MS among the subjects diagnosed
with pre-diabetes, T2DM and high CVD risk. In our data, the highest
prevalence of MS was observed when the JIS definition of MS was
applied, possibly because abdominal obesity is not mandatory in
this definition. Pre-diabetes and T2DM are known risk factors for
atherosclerotic CVD [48], and the MS in T2DM patients issignificantly associated with macro- and microvascular complica-
tions [46]. Recently Brazil has experienced a growing epidemic of
obesity, hypertension, physical inactivity and T2DM. CVDs have
become a major public health problem, since they constitute the
main cause of death in the country [49]. Diabetes is a costly con-
dition, and a large proportion of these expenditures are related to
treating its complications. Intensive interventions involving mul-
tiple cardiovascular risk factors should be implemented to prevent
or reduce the impact of further complications, which could
potentially lead to health cost savings [50].
We examined the diagnostic performances of the different
definitions of MS to identify those with pre-diabetes, T2DM, and
people with high CVD risk. The JIS and IDF definitions presented
higher sensitivity in the identification of participants with these 3
conditions. This difference may be due to the lower WC cut-off
point applied by these definitions. These findings may indicate
that applying the South Asian WC cut-offs as suggested by the IDF
(90 cm for males and 80 cm for females) in the definition of MS
may be a better predictor for pre-diabetes, T2DM and CVD risk in
our population.
This was a population-based study from a semi-urban area in
Northeastern Brazil. The subjects were randomly selected, and the
participation rate was high. Although the final sample was rela-
tively small, it was large enough to meet the required sample size
for analysis. The survey was performed by thoroughly trained and
highly motivated personnel. Collection, transportation, and storage
of the blood samples followed standard procedures and the ana-
lyses were performed in a certified laboratory. Considering the
substantial socioeconomic, ethnic, and regional disparities in Brazil,
generalization of our findings should be done with caution. How-
ever, since Brazilians have a mixed background in general, our
sample might be a good representation of the country’s population.
Another limitation was the cross-sectional design of the study, as a
cause-effect relationship could not be established. Therefore, long-
term prospective studies are needed to confirm the association
between the aforementioned factors and MS.
In conclusion, our study showed that MS is common in Brazil
following the IDF, Modified NCEP and JIS definitions. Although all
three definitions may be appropriate to assess the prevalence of
MS, the IDF and JIS criteria may be better suited in the Brazilian
population to predict pre-diabetes, T2DM and CVD risk. MS is
highly prevalent among subjects with pre-diabetes, T2DM and CVD
risk. Therefore, screening of MS in primary care centers, especially
among women, may identify patients at higher risk of these con-
ditions, and timely intensive multifactorial interventions could
benefit this population.
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